Can a common supplement protect the liver during cancer treatment?

Original Title

The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

Doctors gave a supplement called NAC to patients getting strong chemo before a bone marrow transplant to see if it helped their liver. It did help lower some liver damage signs, but didn't change survival or other big problems.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

NAC normalized liver enzymes in 30% of patients with severe pre-treatment elevations, yet didn’t reduce death rates.

Common sense says fixing liver damage should improve survival—but here, the biomarker improved without changing outcomes, suggesting bilirubin is a marker, not a driver, of mortality.

Practical Takeaways

Patients undergoing busulphan-based transplant should ask their oncologist about prophylactic NAC (100 mg/kg twice daily) to reduce liver enzyme spikes and jaundice risk.

medium confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

36%
Lower QualityOverall Score

Publication

Journal

Scientific Reports

Year

2018

Authors

Ibrahim El-Serafi, M. Remberger, A. El-Serafi, Fadwa Benkessou, Wenyi Zheng, E. Martell, P. Ljungman, J. Mattsson, Moustapha Hassan

Open Access
15 citations
Analysis v1